A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Recruiting · NCT05824975 · Registry updated 2024-11-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Liver Neoplasms, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, colonic disorder, colorectal neoplasm, cutaneous melanoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, liver disorder, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, rectal disorder, renal cell carcinoma, sarcoma, skin disorder, skin neoplasm, type 1 diabetes mellitus 12, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2024-11-25 | NCT05824975 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| GI Innovation, Inc. | 4 |
| Merck Sharp & Dohme LLC | 650 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Asan Medical Center | Seoul | South Korea | 338 |
| Cleveland Clinic | Cleveland | United States | 558 |
| Mayo Clinic in Arizona | Scottsdale | United States | 191 |
| Mayo Clinic in Florida | Jacksonville | United States | 89 |
| Mayo Clinic in Minnesota | Rochester | United States | 5 |
| Memorial Sloan-Kettering Cancer Center | New York | United States | 63 |
| Samsung Medical Center | Seoul | South Korea | 375 |
| Seoul National University Hospital | Seoul | South Korea | 31 |
| St. Vincent's Hospital | Suwon | South Korea | 1 |
| Yonsei University Health System, Severance hospital | Seoul | South Korea | 13 |